Generation of a Chinese hamster ovary cell line producing recombinant human glucocerebrosidase

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Novo, Juliana Branco ^a,b   Morganti, Ligia ^c   Moro, Ana Maria ^a   Paes Leme, Adriana Franco ^a   Serrano, Solange Maria De Toledo ^a   Raw, Isaias ^a   Ho, Paulo Lee ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; METHOTREXATE; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; CELL CLONE; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENETIC TRANSFECTION; GLYCOSYLATION; IMMUNOBLOTTING; NONHUMAN; PRODUCTIVITY; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CRICETULUS; CYTOLOGY; GENETICS; HAMSTER; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MOLECULAR CLONING; PHYSIOLOGY; PROTEIN ENGINEERING;

CRICETULUS GRISEUS;

ANIMALS; CHO CELLS; CLONING, MOLECULAR; CRICETINAE; CRICETULUS; GLUCOSYLCERAMIDASE; HUMANS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 84871836183     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/875383     Document Type: Article

References (59)

1. Erickson A. H., Ginns E. I., Barranger J. A., Biosynthesis of the lysosomal enzyme glucocerebrosidase. The Journal of Biological Chemistry 1985 260 26 14319 14324 2-s2.0-0022386744 (Pubitemid 16197506)
2. Beutler E., Gaucher disease: new molecular approaches to diagnosis and treatment. Science 1992 256 5058 794 799 2-s2.0-0026591232
3. Brady R. O., Kanfer J. N., Shapiro D., Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochemical and Biophysical Research Communications 1965 18 2 221 225 2-s2.0-50549198437
4. Jmoudiak M., Futerman A. H., Gaucher disease: pathological mechanisms and modern management. British Journal of Haematology 2005 129 2 178 188 2-s2.0-17644422131 10.1111/j.1365-2141.2004.05351.x (Pubitemid 40562438)
5. Elstein D., Zimran A., Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009 3 407 417
6. Grabowski G. A., Recent clinical progress in Gaucher disease. Current Opinion in Pediatrics 2005 17 4 519 524 2-s2.0-23344450917 10.1097/01.mop. 0000172702.33128.19 (Pubitemid 41104070)
7. Barranger J. A., O'Rourke E., Lessons learned from the development of enzyme therapy for Gaucher disease. Journal of Inherited Metabolic Disease 2001 24 2, supplement 89 96 2-s2.0-0035153479 10.1023/A:1005695831875 (Pubitemid 33061638)
8. Grabowski G. A., Phenotype, diagnosis, and treatment of Gaucher's disease. The Lancet 2008 372 9645 1263 1271 2-s2.0-53049096591 10.1016/S0140-6736(08)61522-6
9. Beutler E., Enzyme replacement in Gaucher disease. PLoS Medicine 2004 1, article e21 118 121 2-s2.0-15744381966 10.1371/journal.pmed.0010021 (Pubitemid 40412713)
10. Brady R. O., Pentchev P. G., Gal A. E., Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. The New England Journal of Medicine 1974 291 19 989 993 2-s2.0-0016201884
11. Kacher Y., Brumshtein B., Boldin-Adamsky S., Toker L., Shainskaya A., Silman I., Sussman J. L., Futerman A. H., Acid β -glucosidase: onsights from structural analysis and relevance to Gaucher disease therapy. Biological Chemistry 2008 389 11 1361 1369 2-s2.0-56549109938 10.1515/BC.2008.163
12. Starzyk K., Richards S., Yee J., Smith S. E., Kingma W., The long-term international safety experience of imiglucerase therapy for Gaucher disease. Molecular Genetics and Metabolism 2007 90 2 157 163 2-s2.0-33846197993 10.1016/j.ymgme.2006.09.003 (Pubitemid 46108612)
13. Deegan P. B., Cox T. M., Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Design, Development and Therapy 2012 6 81 106
14. Cox T. M., Gaucher disease: clinical profile and therapeutic developments. Biologics 2011 4 299 313
15. Aerts J. M. F. G., Yasothan U., Kirkpatrick P., Velaglucerase alfa. Nature Reviews Drug Discovery 2010 9 11 837 838 2-s2.0-78049488936 10.1038/nrd3311
16. Traynor K., Taliglucerase alfa approved for Gaucher disease. American Journal of Health-System Pharmacy 2012 69 12 1009
17. Brumshtein B., Salinas P., Peterson B., Chan V., Silman I., Sussman J. L., Savickas P. J., Robinson G. S., Futerman A. H., Characterization of gene-activated human acid- β -glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010 20 1 24 32 2-s2.0-70849126444 10.1093/glycob/cwp138
18. Morris J. L., Velaglucerase alfa for the management of type 1 Gaucher disease. Clinical Therapeutics 2012 34 259 271 10.1016/j.clinthera.2011.12.017
19. Zimran A., Loveday K., Fratazzi C., Elstein D., A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Blood Cells, Molecules, and Diseases 2007 39 1 115 118 2-s2.0-34248504877 10.1016/j.bcmd.2007.02.008 (Pubitemid 46754922)
20. Hollak C. E., An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evidence 2012 7 15 20
21. Shaaltiel Y., Bartfeld D., Hashmueli S., Baum G., Brill-Almon E., Galili G., Dym O., Boldin-Adamsky S. A., Silman I., Sussman J. L., Futerman A. H., Aviezer D., Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnology Journal 2007 5 5 579 590 2-s2.0-34547586616 10.1111/j.1467-7652. 2007.00263.x (Pubitemid 47196361)
22. Hollak C. E. M., vom Dahl S., Aerts J. M. F. G., Belmatoug N., Bembi B., Cohen Y., Collin-Histed T., Deegan P., van Dussen L., Giraldo P., Mengel E., Michelakakis H., Manuel J., Hrebicek M., Parini R., Reinke J., di Rocco M., Pocovi M., Sa Miranda M. C., Tylki-Szymanska A., Zimran A., Cox T. M., Force Majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells, Molecules, and Diseases 2010 44 1 41 47 2-s2.0-73049102077 10.1016/j.bcmd.2009.09.006
23. Beutler E., Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proceedings of the National Academy of Sciences of the United States of America 1993 90 12 5384 5390 2-s2.0-0027263071 (Pubitemid 23176164)
24. Beutler E., Lysosomal storage diseases: natural history and ethical and economic aspects. Molecular Genetics and Metabolism 2006 88 3 208 215 2-s2.0-33745506072 10.1016/j.ymgme.2006.01.010 (Pubitemid 43963435)
25. Futerman A. H., Sussman J. L., Horowitz M., Silman I., Zimran A., New directions in the treatment of Gaucher disease. Trends in Pharmacological Sciences 2004 25 3 147 151 2-s2.0-1342306744 10.1016/j.tips.2004.01.004 (Pubitemid 38264505)
26. Kaufman R. J., Davies M. V., Wasley L. C., Michnick D., Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Research 1991 19 16 4485 4490 2-s2.0-0026431613 (Pubitemid 21912828)
27. Urlaub G., Chasin L. A., Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proceedings of the National Academy of Sciences of the United States of America 1980 77 7 4216 4220 2-s2.0-0001127374 (Pubitemid 10022580)
28. Cacciatore J. J., Chasin L. A., Leonard E. F., Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnology Advances 2010 28 6 673 681 2-s2.0-77957018662 10.1016/j.biotechadv.2010.04.003
29. Kaufman R. J., Selection and coamplification of heterologous genes in mammalian cells. Methods in Enzymology 1990 185 537 566 2-s2.0-0025365149 10.1016/0076-6879(90)85044-O (Pubitemid 20219847)
30. Jayapal K. P., Wlaschin K. F., Hu W. S., Yap M. G. S., Recombinant protein therapeutics from CHO Cells-20 years and counting. Chemical Engineering Progress 2007 103 10 40 47 2-s2.0-41849140828
31. Wurm F. M., Production of recombinant protein therapeutics in cultivated mammalian cells. Nature Biotechnology 2004 22 11 1393 1398 2-s2.0-8344271026 10.1038/nbt1026 (Pubitemid 39482858)
32. Sanger F., Nicklen S., Coulson A. R., DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences of the United States of America 1977 74 12 5463 5467 2-s2.0-0017681196
33. Graham F. L., van der Eb A. J., A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973 52 2 456 467 2-s2.0-0015847039
34. Novo J. B., Oliveira M. L. S., Magalhães G. S., Morganti L., Raw I., Ho P. L., Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in escherichia coli. Molecular Biotechnology 2010 46 3 279 286 2-s2.0-77958089351 10.1007/s12033-010-9303-4
35. Stoscheck C. M., Quantitation of protein. Methods in Enzymology 1990 182 50 68 2-s2.0-0025211779 10.1016/0076-6879(90)82008-P (Pubitemid 20154379)
36. Bergmann J. E., Grabowski G. A., Posttranslational processing of human lysosomal acid β -glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. American Journal of Human Genetics 1989 44 5 741 750 2-s2.0-0024542617 (Pubitemid 19119987)
37. Leonova T., Grabowski G. A., Fate and sorting of acid β -glucosidase in transgenic mammalian cells. Molecular Genetics and Metabolism 2000 70 4 281 294 2-s2.0-0033795520 10.1006/mgme.2000.3035
38. Beck M., Therapy for lysosomal storage disorders. IUBMB Life 2010 62 1 33 40 2-s2.0-77950586398 10.1002/iub.284
39. Berg-Fussman A., Grace M. E., Ioannou Y., Grabowski G. A., Human acid β -glucosidase. N-glycosylation site occupancy and the effect of glycosylation on enzymatic activity. The Journal of Biological Chemistry 1993 268 20 14861 14866 2-s2.0-0027179238 (Pubitemid 23206631)
40. Grace M. E., Grabowski G. A., Human acid β -glucosidase: glycosylation is required for catalytic activity. Biochemical and Biophysical Research Communications 1990 168 2 771 777 2-s2.0-0025284194 10.1016/0006-291X(90)92388-G (Pubitemid 20164609)
41. Brooks S. A., Appropriate glycosylation of recombinant proteins for human use: implications of choice of expression system. Applied Biochemistry and Biotechnology-Part B 2004 28 3 241 256 2-s2.0-21644462706 10.1385/MB:28:3:241 (Pubitemid 41490569)
42. Durocher Y., Butler M., Expression systems for therapeutic glycoprotein production. Current Opinion in Biotechnology 2009 20 6 700 707 2-s2.0-70449710875 10.1016/j.copbio.2009.10.008
43. Walsh G., Post-translational modifications of protein biopharmaceuticals. Drug Discovery Today 2010 15 17-18 773 780 2-s2.0-77956458110 10.1016/j.drudis.2010.06.009
44. Rasmussen J., Barsomian G., Bergh M., Enzymatically active recombinant glucocerebrosidase. US Patent, 5, 236, 838, 1993
45. Chura-Chambi R. M., Tornieri P. H., Spencer P. J., Nascimento P. A., Mathor M. B., Morganti L., High-level synthesis of recombinant murine endostatin in Chinese hamster ovary cells. Protein Expression and Purification 2004 35 1 11 16 2-s2.0-16544366737 10.1016/j.pep.2004.01.003 (Pubitemid 38497900)
46. Peroni C. N., Soares C. R. J., Gimbo E., Morganti L., Ribela M. T. C. P., Bartolini P., High-level expression of human thyroid-stimulating hormone in Chinese hamster ovary cells by co-transfection of dicistronic expression vectors followed by a dual-marker amplification strategy. Biotechnology and Applied Biochemistry 2002 35 1 19 26 2-s2.0-0036182506 10.1042/BA20010061 (Pubitemid 34171375)
47. Soares C. R. J., Morganti L., Miloux B., Lupker J. H., Ferrara P., Bartolini P., High-level synthesis of human prolactin in Chinese-hamster ovary cells. Biotechnology and Applied Biochemistry 2000 32 2 127 135 2-s2.0-0033770925
48. Kuystermans D., Krampe B., Swiderek H., Al-Rubeai M., Using cell engineering and omic tools for the improvement of cell culture processes. Cytotechnology 2007 53 1-3 3 22 2-s2.0-34250647014 10.1007/s10616-007-9055-6 (Pubitemid 46944875)
49. Hacker D. L., De Jesus M., Wurm F. M., 25years of recombinant proteins from reactor-grown cells-where do we go from here? Biotechnology Advances 2009 27 6 1023 1027 2-s2.0-70349765751 10.1016/j.biotechadv.2009.05.008
50. Browne S. M., Al-Rubeai M., Selection methods for high-producing mammalian cell lines. Trends in Biotechnology 2007 25 9 425 432 2-s2.0-35548990601 10.1016/j.tibtech.2007.07.002 (Pubitemid 350147111)
51. Takasaki S., Murray G. J., Furbish F. S., Structure of the N-asparagine-linked oligosaccharide units of human placental β -glucocerebrosidase. The Journal of Biological Chemistry 1984 259 16 10112 10117 2-s2.0-0021164336 (Pubitemid 14067685)
52. Van Patten S. M., Hughes H., Huff M. R., Piepenhagen P. A., Waire J., Qiu H., Ganesa C., Reczek D., Ward P. V., Kutzko J. P., Edmunds T., Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007 17 5 467 478 2-s2.0-34447309572 10.1093/glycob/cwm008 (Pubitemid 47049935)
53. Friedman B., Hayes M., Enhanced in vivo uptake of glucocerebrosidase. US Patent, 5, 549, 892, 1996
54. Furbish F. S., Steer C. J., Krett N. L., Barranger J. A., Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochimica et Biophysica Acta 1981 673 4 425 434 2-s2.0-0019475525 (Pubitemid 11103742)
55. Fann C. H., Guirgis F., Chen G., Lao M. S., Piret J. M., Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. Biotechnology and Bioengineering 2000 69 2 204 212 2-s2.0-0034691696 (Pubitemid 30430091)
56. Kim N. S., Kim S. J., Lee G. M., Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. Biotechnology and Bioengineering 1998 60 679 688 (Pubitemid 28513918)
57. Chusainow J., Yang Y. S., Yeo J. H. M., Ton P. C., Asvadi P., Wong N. S. C., Yap M. G. S., A study of monoclonal antibody-producing CHO cell lines: what makes a stable high producer? Biotechnology and Bioengineering 2009 102 4 1182 1196 2-s2.0-60549102844 10.1002/bit.22158
58. Gu M. B., Kern J. A., Todd P., Kompala D. S., Effect of amplification of dhfr and lac Z genes on growth and β -galactosidase expression in suspension cultures of recombinant CHO cells. Cytotechnology 1992 9 1-3 237 245 2-s2.0-0027022939 10.1007/BF02521751
59. Hoppe H., Cerezyme-recombinant protein treatment for Gaucher's disease. Journal of Biotechnology 2000 76 2-3 259 261 2-s2.0-0034695288